Global Drugs for Herpes Labialis (Oral Herpes) Market Growth (Status and Outlook) 2023-2029

Global Drugs for Herpes Labialis (Oral Herpes) Market Growth (Status and Outlook) 2023-2029

Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.
LPI (LP Information)' newest research report, the “Drugs for Herpes Labialis (Oral Herpes) Industry Forecast” looks at past sales and reviews total world Drugs for Herpes Labialis (Oral Herpes) sales in 2022, providing a comprehensive analysis by region and market sector of projected Drugs for Herpes Labialis (Oral Herpes) sales for 2023 through 2029. With Drugs for Herpes Labialis (Oral Herpes) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drugs for Herpes Labialis (Oral Herpes) industry.
This Insight Report provides a comprehensive analysis of the global Drugs for Herpes Labialis (Oral Herpes) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drugs for Herpes Labialis (Oral Herpes) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Drugs for Herpes Labialis (Oral Herpes) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drugs for Herpes Labialis (Oral Herpes) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drugs for Herpes Labialis (Oral Herpes).
The global Drugs for Herpes Labialis (Oral Herpes) market size is projected to grow from US$ 2404.5 million in 2022 to US$ 3402.2 million in 2029; it is expected to grow at a CAGR of 5.1% from 2023 to 2029.
Global Drugs for Herpes Labialis (Oral Herpes) key players include GSK, Novartis, Teva, Mylan, Cadila, etc. Global top five manufacturers hold a share about 55%. North America is the largest market, with a share about 35%, followed by Europe, with a share about 30 percent. In terms of product, Rx Drugs is the largest segment, with a share about 90%. And in terms of application, the largest application is Oral, followed by External Use, and Injection, etc.
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Herpes Labialis (Oral Herpes) market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Aciclovir
Valacyclovir
Famciclovir
Docosanol
Other
Segmentation by application
External Use
Oral
Injection
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GSK
Novartis
Teva
Mylan
Cadila
Apotex
Daewoong Pharmaceutical
Livzon
Luoxin
Med shine
Bayer (Campho Phenique)
Blistex
Kelun
Hikma
Haiwang
Carmex
Cipher

Please note: The report will take approximately 2 business days to prepare and deliver.